{"name":"Swedish Orphan Biovitrum (Sobi)","slug":"sobi","ticker":"SOBI.ST","exchange":"Nasdaq Stockholm","domain":"sobi.com","description":"Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.","hq":"Stockholm, Sweden","founded":1999,"employees":"1862","ceo":"Guido Oelkers","sector":"Rare Disease / Specialty Pharma","stockPrice":405.6,"stockChange":12.4,"stockChangePercent":3.15,"marketCap":"$140.8B","metrics":{"revenue":28238000128,"revenueGrowth":5.2,"grossMargin":78.9,"rdSpend":0,"netIncome":478000000,"cash":1041000000,"dividendYield":0,"peRatio":298.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Vonjo first approved","drug":"Vonjo","drugSlug":"pacritinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Elocta patent cliff ($1.2B at risk)","drug":"Elocta","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Vonvendi patent cliff ($0.8B at risk)","drug":"Vonvendi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Vonjo","genericName":"PACRITINIB","slug":"pacritinib","indication":"Myelofibrosis","status":"marketed"}]}],"pipeline":[{"name":"Vonjo","genericName":"PACRITINIB","slug":"pacritinib","phase":"marketed","mechanism":"Vonjo works by blocking the activity of the JAK2 enzyme, which is overactive in myelofibrosis patients.","indications":["Myelofibrosis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-08","type":"earnings","headline":"Sobi Reports Fourth Quarter and Full Year 2023 Results","summary":"Sobi reported a net sales increase of 12% in the fourth quarter and 10% for the full year 2023, driven by strong growth in its hemophilia and immunology franchises.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Sobi and Pfizer Announce Collaboration to Develop and Commercialize Sobi's Gene Therapy for Hemophilia A","summary":"Sobi and Pfizer announced a collaboration to develop and commercialize Sobi's gene therapy for hemophilia A, with Pfizer acquiring an option to co-promote the therapy in the US.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"pipeline","source":"simplywall.st","summary":"A Look At Swedish Orphan Biovitrum (OM:SOBI) Valuation After Recent Share Price Momentum - simplywall.st","headline":"A Look At Swedish Orphan Biovitrum (OM:SOBI) Valuation After Recent Share Price Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNRXZYM0EyVDgwcVdLRXVWdFRjODhYNXFVODNrbGo5TGNQNFRLN2ZNdEJlQWh4N0RxVHREYlVKLVY2ZkFrQ3Nib2xGUHNJMFNzOWlhZlVCYjVGbzIzajRJREJYV2dZVVlYNno3RDRjSzJrM01JNlNOLVBjZzBtaVVsU1pMR2VKVjFySGFaVnl4TGtCbW5iMTB0cmZ4eVA2cDdUSXlpR1FCVVlCRFBKTUVUNFFKTFhnWllxSWx1bWZ6MFQxcWlVZnVzcXRjZThWMjhHQUJ5dnE5TGI5SWplQU1aWDNoRzE4b2hwM1Z2OURBSGFEM2vSAfgBQVVfeXFMTXpSVzVwSEkzUnFUSlVkNWpqNl9RbUJNVnRnTUNncUpVMW1PNGtEXzE4cHZLd1hCZ0NaeTVkenpuWUcxYXNkOGhCRGMtZ2x0bHRpbnFBMEdEZEctRHBMZ1kyUXFQZnpnTHpFemFFOWxoNG5val83QXlPRUtJRUVZOGJYS0xuNktpWDJOVHY3elh2Z3ZMRWhhTXdpcjc1a3psc3hVSVFQMXJwdGVtVkpUTFVKa3k1Z3Q1NFJJdnNDaWFndUlHTTBsT2dEMHdYRlRHQVdkRkRwZlc0cENZV3pseHU2aXNZb0YxZ1NYMlMtOXpfZVV5ODZGSm4?oc=5","date":"2026-03-31","type":"regulatory","source":"simplywall.st","summary":"EMA Tryngolza Review And Gamifant Data Reframe Sobi’s Growth Story - simplywall.st","headline":"EMA Tryngolza Review And Gamifant Data Reframe Sobi’s Growth Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOd0M1MUZwMVlMekNSZlNlTW9BVU5UMDQwS0NpLTR3cC0wWnVEMnhFN1lrUE9kbUtSSy1jYXRZNFhicHRheFZDdFEzVVBCVEYyeTQ5RlJZdTdycmYyRU4zOU5qZm5aQ2o4bE5LWW92ZnB6OEdEemxJZDRfR24zMHRDd21kY3VQRFl1SEtsRkZlcV9JV1EtMkZz?oc=5","date":"2026-02-05","type":"pipeline","source":"The Pharma Letter","summary":"Sobi reports 4th-qrt and full year 2025 results - The Pharma Letter","headline":"Sobi reports 4th-qrt and full year 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBVNkduTkRNYi1FeENUM2t0T1l5dWV0MWRRc3prWmNnMEdYOWtqWFBsa2JibktxM2NHanJ2NW1KeWxpSXNzYThGZS1ZVmhIaXNIOFlv?oc=5","date":"2026-01-16","type":"pipeline","source":"firstwordpharma.com","summary":"EU expands Sobi's Aspaveli for rare kidney diseases - firstwordpharma.com","headline":"EU expands Sobi's Aspaveli for rare kidney diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE43TGlpSXJubENFMzVjUjhST2pFek9hS1M1OHcyZy1oRlJzc2VaUlRJNUt4TXJHWXpQY3htai00ZElGbUZnRmVCeUlfc2h3T2lzZ21jVnRqaXV0WEI3aEwxemRDVXpfeVNzVmdiakhhYw?oc=5","date":"2025-12-15","type":"deal","source":"medwatch.com","summary":"Sweden's Sobi acquires US biotech for up to USD 1.5bn - medwatch.com","headline":"Sweden's Sobi acquires US biotech for up to USD 1.5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWEdDN3MzNHQyakxCM1JfUGZ4WllmNFFvWG5vSGFseHZ1T1hCNm94T05LYm5YVUVORXRqdnE2TzBsaFg1LUh0Y1lxRXV5cWE1MXhvX01tdEsyU2dzejBHLVFTT0hQQTJUM3plSmdfc3QxVFlieFA2Q2xNSGtKcWFWZ1RySHhCci05UHQ0eWJUMFFxZWxw?oc=5","date":"2025-12-15","type":"deal","source":"Contract Pharma","summary":"SOBI Agrees to Acquire Arthrosi Therapeutics - Contract Pharma","headline":"SOBI Agrees to Acquire Arthrosi Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPVDJjZC1hZUJkTWdNdzV2dFZmY3pJc19TZUlBakN0akxUZEI1QVR0dS1VeC1ha3ktX041OE9fSTQ5Rndqb2kzMmI4Zld0Q05iS0FCNEhRcTBxSUljblRNVXJVc3I2SUpkRFlDdlR5ZlhRX2lIV1p2RHlBdTJQQmhzNVpRME5UN1NKdjFLTlVpRDhvLXZrWWJDanhtLUVJcDNkS1Q1N2ZNSW5hYUZJYTNHM09ic3VwWmRYOGZTczBsWC1ZOHI2dHlPMWNLangwNTZKUEtyVXhkQU5rLWdwNXR3VHlRMFU2SmFacFZCS0ljQVhyMURM0gH6AUFVX3lxTE5WSVpHaWtrX1U0bDhjMElsejg4VkJEYUE5TVNwcThzeXNBeDJybks0NFJzeWdUbExyU244ZUlaeEFOYkMxOHF0enlvQ2kyLUZSaHg2OFZvTlJyVmEta3BaWC14X2hWNGhMZ21MV3FFdDlxdlkzbTlJeFpieEhfcTgtSkpVUm5PMlNDZXN5aXFVa1EzRDIycWllYzhwUk1mQ1lVOGg3ckthekdmLTl5TFRaNWdSSksxS1dTbDhFSGdvdEJiM3VCNjdpYW41WFRPaGkyeEJydE8tUnltc3U3aUVYczZmTFRseTRFbm9HYnZFU3J2dXlWaWh3a3c?oc=5","date":"2025-12-01","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-19","type":"pipeline","source":"simplywall.st","summary":"Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors - simplywall.st","headline":"Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1qOFZuYkpPMEViOTJrLTNReGJIUVFHaUIxV2hueUpRQkpCY2ZYbW9PVG95ZC1XUjNHVElSTzlleDN6ZENqM2tKbFUzUi04LVVfcGg2NUNwREloM2pkVmJIUGJWMjZ6VElIdk9YSzd2TDR5VmltOUlKXzhuZ2FzbTg?oc=5","date":"2025-09-14","type":"pipeline","source":"Yahoo Finance","summary":"Is Sobi Set for a Rebound After Shares Drop 16% in 2024? - Yahoo Finance","headline":"Is Sobi Set for a Rebound After Shares Drop 16% in 2024?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNQTlsTV9FN0dfZi1RY3BSdTByYUJ5Q1VlT045LVB6ZC00WkhxemlUcWJSX09JbVRCeEx1WGZZN3pHUlhLYy03TnFoOEJobmxWUk82WEU1UTNuY0lGQ3VYMzFwajF0SG94bDR4V2x2ZlFJcWRJeU9kMXJLVExrSXU3ZU9sUVgzWDRxb29HVHZqTTFMRU9TQ1c5elFhZmIzSVBnU18tczBSM2otTjFRY0ZUeHFB?oc=5","date":"2025-07-16","type":"pipeline","source":"bloomberg.com","summary":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’ - bloomberg.com","headline":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxObFV1Tm1Sb2J5Z25DdmYzLWM1ejdFdWxEX2YyaGkwRTlDZ1JCb05ka24xVDlvdm51eDlBTUlGeEx2dTVSOWNHdUJtdmJidWJ6UGFLMF9keWFLZm5pWENHa3NWU0o2aE1zMmx2RVJDdVcyWWdGaGZUQldVZlBnZzZVX05TdTRQNktLbjFvcFlZMjhzNHhTTy1mOUVVLWFONFJKdjltRWRzeUNER2FkalNTRUxQb09rLVBxSUZ1dzV0SmRHUHVPU1I2RnFRNDVLOFBUZ2JwR2Jn?oc=5","date":"2022-10-06","type":"pipeline","source":"DCAT Value Chain Insights","summary":"Women Leaders in Pharma Interview: Tarita Qveflander, Sobi – Swedish Orphan Biovitrum AB - DCAT Value Chain Insights","headline":"Women Leaders in Pharma Interview: Tarita Qveflander, Sobi – Swedish Orphan Biovitrum AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBqVEZWc0xpeGJLQ3MyWEJXcXh2dVF2b0RYekhHZXhZWU9UdVU5ZEdLNUcxeE4wb182UF9NNW1oV2hiWGdkOE8ySURjVDZTRms3TTRnc3NR?oc=5","date":"2017-05-23","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Swedish Orphan Biovitrum AB (publ) (SOBI.ST) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Swedish Orphan Biovitrum AB (publ) (SOBI.ST) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Elocta","drugSlug":"rfviiifc","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Vonvendi","drugSlug":"rfviiifc","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"EU","annualRevenue":800000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Biogen","Shire"],"therapeuticFocus":["Hemophilia","Primary Immunodeficiency","Rare Diseases"],"financials":null,"yahoo":{"currentPrice":405.6,"previousClose":393.2,"fiftyTwoWeekHigh":432.8,"fiftyTwoWeekLow":241.8,"fiftyTwoWeekRange":"241.8 - 432.8","fiftyDayAverage":384.21,"twoHundredDayAverage":326.05,"beta":0.23,"enterpriseValue":146373738496,"forwardPE":26.1,"priceToBook":3.72,"priceToSales":4.99,"enterpriseToRevenue":5.18,"enterpriseToEbitda":12.88,"pegRatio":0.37,"ebitda":11361999872,"ebitdaMargin":40.2,"freeCashflow":5223000064,"operatingCashflow":8565000192,"totalDebt":11495000064,"debtToEquity":30.5,"currentRatio":0.9,"returnOnAssets":7,"returnOnEquity":1.2,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":428.5,"targetHighPrice":500,"targetLowPrice":308,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.1,"institutionHeldPercent":72.5,"sharesOutstanding":345845189,"floatShares":221730900,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.36,"epsForward":15.55,"revenuePerShare":82.02,"bookValue":109.12,"officers":[{"age":60,"name":"Dr. Guido  Oelkers Ph.D.","title":"CEO & President"},{"age":58,"name":"Mr. Henrik  Stenqvist M.Sc.","title":"Chief Financial Officer"},{"age":null,"name":"Gerard  Tobin","title":"Head of Investor Relations"},{"age":56,"name":"Mr. Torbjörn  Hallberg","title":"General Counsel & Head of Legal Affairs"},{"age":57,"name":"Ms. Lena  Bjurner","title":"Head of People & Communication"},{"age":45,"name":"Mr. Daniel  Rankin","title":"Head of Strategy & Corporate Development"},{"age":58,"name":"Mr. Norbert  Oppitz","title":"Head of International"},{"age":53,"name":"Mr. Sofiane  Fahmy","title":"Head of Europe"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.sobi.com","phone":"46 86 97 20 00"}}